Cost-effective drug selection: Antiplatelet agents

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Although others may be used on an occasional basis, the main antiplatelet classes utilized to prevent and treat cardiovascular disease are aspirin, ADP antagonists, and glycoprotein (GP) IIb/IIIa receptor inhibitors. These agents have shown their clinical benefits in a wide variety of well-designed clinical trials. As health care advances into the new millennium, the clinical benefits of medical therapies need to be accompanied by an economic analysis of this benefit. For clinicians to make cost-effective selection of antiplatelet agents, the efficacy, safety and pharmacoeconomic data all need to be considered.

Original languageEnglish (US)
Title of host publicationClinical, Interventional and Investigational Thrombocardiology
PublisherCRC Press
Pages169-180
Number of pages12
ISBN (Electronic)9780849344954
ISBN (Print)0824754190, 9780824754198
StatePublished - Jan 1 2005

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Cost-effective drug selection: Antiplatelet agents'. Together they form a unique fingerprint.

Cite this